Key Drivers
- High margins
- Strong liquidity
- Weaker conversion
AIAI Summary
HRMY should be viewed less as a speculative biotech and more as a profitable WAKIX-led commercial franchise with real cash flow and reaffirmed 2026 guidance, but the stock's upside now hinges on sustaining that core growth while overcoming recurring market-access pressure and proving pipeline diversification beyond a single product.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High margins
- •Strong liquidity
- •Weaker conversion
HRMY looks fundamentally strong thanks to high margins, robust cash generation, and a clean balance sheet, but the latest quarter showed weaker operating conversion and heavy investing outflows, making valuation reasonable but not a clear bargain.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Strong momentum
- •Extended advance
HRMY is still in a constructive short-term uptrend with higher highs and higher lows above its last month moving average, but after a sharp run to $37.26 it looks stretched and needs to hold mid-$35 support to avoid a pullback.
Sharp multi-week climb from the low $32s to a new high leaves the stock short-term extended
Sentiment & News
Key News Insights:
- •Wakix Dependence
- •Pipeline Diversification
- •Conference Visibility
Harmony Biosciences is showing discounted, neutral-to-mixed sentiment as Wakix remains the core growth driver while management pushes pipeline diversification and maintains active investor/scientific outreach.
The news suggests limited near-term upside until Harmony proves broader pipeline execution beyond Wakix, though ongoing research and outreach support longer-term optionality
Similar Companies in Healthcare
Other companies in the same sector with AI ratings